Related Experiment Video

Updated: Oct 6, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Marco H Hofmann1, Daniel Gerlach1, Sandra Misale2

  • 1Discovery Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Cancer Discovery
|January 20, 2022
PubMed

Insights

Targeting KRAS mutations in cancer is advancing rapidly. New allele-specific and pan-KRAS inhibitors offer hope for broader patient populations beyond KRASG12C-mutated cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS is the most frequently mutated oncogene, found in about 14% of all cancers.
  • KRASG12C inhibitors have transformed treatment for specific non-small cell lung and colorectal cancers.
  • Targeting KRAS mutations is crucial for developing new cancer therapies.

Purpose of the Study:

  • To review current allele-specific and pan-KRAS inhibition strategies.
  • To discuss the potential utility of these novel therapeutic approaches.
  • To highlight the need for a broader arsenal of KRAS-targeting drugs.

Main Methods:

  • Review of actively pursued allele-specific KRAS inhibition strategies.
  • Review of actively pursued pan-KRAS inhibition strategies.
  • Analysis of potential patient populations for these therapies.

Main Results:

  • Mutant-selective KRASG12C inhibitors currently target a subset of KRAS-driven cancers.
  • Pan-KRAS drugs show potential for treating various KRAS alterations, including KRASG12D, KRASG12V, and resistance to KRASG12C inhibitors.
  • Future KRAS medicines are expected to include both mutant-selective and pan-KRAS therapeutics.

Conclusions:

  • Developing a comprehensive set of KRAS drugs is essential for effectively treating KRAS-driven cancers.
  • Both allele-specific and pan-KRAS strategies are vital for addressing diverse KRAS alterations.
  • These advancements promise to expand treatment options for a wider range of cancer patients.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K